EDITAS MEDICINE INC.
EDITAS MEDICINE INC.
- USD (-)
- 15 min delayed data - NASDAQ Stocks
Open: -
Change: -
Volume: -
Low: -
High: -
High / Low range: -
Type: Stocks
Ticker: EDIT
ISIN:

Editas Medicine to Host Conference Call Discussing First Quarter 2019 Results and Corporate Update

  • 23

CAMBRIDGE, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, May 7, 2019, at 5:00 p.m. ET to discuss a corporate update and results for the first quarter of 2019.

To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 8457858. A live webcast of the presentation will be available on the Investors & Media section of the Editas Medicine website.

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

ti?nf=NzYxMjUwMyMyOTE0MjY4IzIwMjYwMjc=
Contacts:
Investors
Mark Mullikin
(617) 401-9083
[email protected]

Media
Cristi Barnett
(617) 401-0113 
[email protected]

Editas-Logo-Small (1).jpg

GlobeNewsWire
GlobeNewsWire

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases, financial disclosures and multimedia content to media, investors, and consumers worldwide.